Turn Therapeutics Finalizes Expanded Phase 2 Design for GX-03 in Atopic Dermatitis
TTRX has more than doubled off its 52-week low of $2.57 on elevated volume (2.3× avg).
Summary
Turn Therapeutics announced the final Stage 2 design for its GX-03 Phase 2 clinical trial in atopic dermatitis, expanding the patient population and optimizing statistical methodology based on positive interim data.
Key Events · Product Development and Regulatory · TTRX
-
Phase 2 Trial Design Finalized
Turn Therapeutics completed a comprehensive interim analysis of its adaptive Phase 2 clinical trial for GX-03 in atopic dermatitis, leading to the final Stage 2 study design.
-
Patient Population Expanded
The Stage 2 program will now prospectively evaluate patients across the full spectrum of baseline Eczema Area and Severity Index (EASI) severity, including mild-to-moderate disease (EASI 1.1-7.0), expanding the potential market.
-
Optimized Statistical Methodology
The final Stage 2 design will employ the FDA-recognized Hochberg multiple testing procedure across four prespecified efficacy endpoints, enhancing the statistical power to demonstrate significance.
-
Positive Interim Efficacy & Safety
Clinically meaningful efficacy was observed across a broader spectrum of atopic dermatitis severity, and GX-03 continues to demonstrate a favorable safety and tolerability profile with no treatment-related serious adverse events.
Analysis · TTRX · Life Sciences
This 8-K details the refined Stage 2 design for Turn Therapeutics' lead drug candidate, GX-03, following a comprehensive interim analysis. The decision to expand the trial to include a broader spectrum of atopic dermatitis severity, including mild-to-moderate patients, significantly increases the potential market opportunity for GX-03. The optimized design, which incorporates the FDA-recognized Hochberg multiple testing procedure and enrichment for baseline pruritus severity, aims to maximize the probability of achieving statistically significant results. This update reinforces the positive momentum from previous interim Phase 2 results and indicates a clear, data-driven path forward for the drug's development.
At the time of this filing, TTRX was trading at $7.99 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $229.1M. The 52-week trading range was $2.57 to $26.50. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.